Key Takeaways; Cannabis Sector

• Trulieve and Green Thumb were Named Among TIME’s America’s Best Companies of 2026 
• Curaleaf Holdings Options Set to Begin Trading on Montréal Exchange 
• Aurora Cannabis Earned TIME Canada Recognition, As the Company Announced Plans to Strengthen Governance Ahead of Annual Meeting 

Key Takeaways; Psychedelic Sector

• Compass Pathways Strengthened Case for FDA Filing as Phase 3 Data Confirmed Durable Benefits of COMP360 
• AtaiBeckley Completed Patient Dosing in Phase 2b VLS-01 Trial, The Company Now Eyes Phase 3 Expansion into Major Depression 

Below is a weekly roundup of what happened this week in the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends.

Top Marijuana Companies for the Week

#1: Trulieve and Green Thumb

Trulieve Cannabis Corp. (NYSE: TRLV) (CSE: TRUL) (OTCQX: TCNNF) and Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) were recognized on TIME magazine’s America’s Best Companies of 2026 list, making them the only two cannabis companies to earn a place among the top 1,000 U.S. companies.

The annual ranking, compiled by TIME in partnership with Statista, evaluated companies based on employee satisfaction, financial performance, and sustainability transparency. Both public and private companies that disclose financial and sustainability data were considered.

Trulieve Chief Executive Officer, Kim Rivers, welcomed the recognition, saying, “Being named to TIME’s list of America’s Best Companies is a tremendous honor and a direct reflection of the durability of our business. To be one of only two cannabis companies recognized speaks to the passion and dedication of our team.”

The recognition marked another milestone for the U.S. cannabis industry as it continues to gain broader corporate recognition despite ongoing federal regulatory constraints. Trulieve recently became the first U.S. cannabis company to list on the New York Stock Exchange after restructuring as a medical cannabis-focused business, while Green Thumb continues to strengthen its market position with steady revenue growth and expanding medical cannabis operations.

According to TIME and Statista, this year’s rankings placed greater emphasis on sustainable financial performance than previous global rankings, highlighting companies that combine strong business results with workforce satisfaction and transparent sustainability practices. 

#2: Curaleaf Holdings

Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) announced it had reached a new capital markets milestone, with exchange-traded options on its subordinate voting shares scheduled to begin trading on the Montréal Exchange (MX) on Monday, July 13 under the ticker symbol CURA.

The company said the exchange-initiated listing reflects its growing market maturity and is expected to provide investors with greater flexibility through hedging, income-generation and directional trading strategies. Curaleaf also believes the move could improve liquidity and price discovery by attracting options traders, market makers and institutional investors.

Chairman and Chief Executive Officer of Curaleaf, Boris Jordan, said the listing demonstrates the company’s progress as a public company. “The listing of exchange-traded options on the Montréal Exchange reflects Curaleaf’s market capitalization, trading depth and growing institutional relevance,” he said. “Because the listing decision rests solely with the Exchange, we view it as independent recognition of the progress we have made as a public company.”

Jordan added that listed options will allow investors to “hedge risk, pursue income strategies and express a view on Curaleaf’s long-term growth—the same tools commonly available to investors in mature equity markets.”

Curaleaf emphasized that the Montréal Exchange independently determines which securities qualify for options trading based on criteria such as market capitalization, share price and trading activity. The company reaffirmed that it did not apply for the listing, and the options contracts are issued between market participants rather than by Curaleaf, meaning there is no share-dilution, no proceeds to the company and no action required from shareholders. 

#3: Aurora Cannabis

Canadian-based Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) marked a significant week with recognition as one of TIME Canada’s Best Companies 2026 while also outlining governance and executive compensation changes ahead of its upcoming Annual General Meeting (AGM).

The company ranked 96th out of 125 on TIME Canada’s Best Companies 2026 list, receiving an overall score of 79.14. Compiled by TIME in partnership with Statista, the rankings are based on three key factors: employee satisfaction, revenue growth, and sustainability transparency. Aurora also made history as the first and only cannabis company to be included on the list.

CEO and Executive Chairman of Aurora, Miguel Martin, welcomed the recognition, saying, “This is a proud milestone for Aurora and a meaningful recognition of our leadership strength in Canada. Above all, this recognition belongs to our people.” He added that the award reflects the company’s progress, credibility, and commitment to advancing the global medical cannabis industry.

Separately, Aurora announced that it had filed and mailed the Management Information Circular for its 2026 Annual General Meeting of Shareholders, which will be held virtually on August 7, 2026. Shareholders were encouraged to review the meeting materials and vote ahead of the August 5 proxy deadline, with the board recommending support for all director nominees and meeting resolutions.

The circular also highlighted changes in executive compensation following shareholder feedback. The company announced that Martin had voluntarily forfeited 50% of the Performance Share Units (PSUs) granted to him in June 2025. 

Looking ahead to fiscal 2027, Aurora said it had approved a reduction in the CEO’s total-target long-term incentive (LTI) grant and restructured its LTI program to place greater emphasis on performance-based compensation.

Top Psychedelic Companies for Week

#1: Compass Pathways

Compass Pathways plc (NASDAQ: CMPS) reported positive six-month results from its ongoing Phase 3 COMP006 trial, reinforcing the rapid and durable efficacy of its investigational COMP360 synthetic psilocybin treatment in patients with treatment-resistant depression (TRD). According to Compass Pathways, the findings strengthen its regulatory package as it continues its rolling New Drug Application (NDA) submission with the U.S. Food and Drug Administration, with final filing expected in the fourth quarter of 2026 and a potential commercial launch in the first half of 2027, subject to approval.

The 26-week data from nearly 600 patients built on the previously reported positive results from the Phase 3 COMP005 trial. The company reported that participants in COMP006 represented a highly chronic TRD population, with depressive episodes lasting more than three years on average and over six lifetime depressive episodes. Among patients receiving the 25 mg dose, 39% achieved a clinically meaningful reduction in depression symptoms by Week 6 after two fixed doses of COMP360, with those benefits maintained through at least Week 26. The response rate compared favorably with the 25% observed in COMP005 after a single dose, suggesting that retreatment may enhance outcomes for some patients.

The company also reported that COMP360 maintained a generally well-tolerated safety profile, with most treatment-emergent adverse events being transient and occurring on the day of dosing. No new safety findings were identified during the trial.

Chief Executive Officer of Compass Pathways, Kabir Nath, said the latest results further strengthen the company’s clinical evidence ahead of regulatory submission. “The COMP006 data further strengthens our robust clinical package for COMP360 and represents an important step toward completing our NDA submission. COMP360 has demonstrated consistent results, with rapid onset and durable benefit for people living with chronic, treatment-resistant depression.”

Nath added that the treatment has the potential to transform mental healthcare by reducing the need for daily medication. “We are convinced this profile will lead to a profound shift in mental health care—moving beyond daily or frequent administration towards an option potentially involving just a few treatments in a year that could be life changing for patients.”

Dr. Guy Goodwin, Chief Medical Officer of Compass Pathways, described the results as a significant milestone for one of psychiatry’s most challenging conditions. “COMP360 has demonstrated rapid, durable and reproducible clinical effects through at least six months—with a consistent safety profile—across two large, well-controlled Phase 3 studies in treatment-resistant depression.”

With these positive results, Compass Pathways now believes the data supports a likely FDA approval in the first half of 2027, while acknowledging that the commercial rollout is expected to build gradually as treatment infrastructure expands.

#2: AtaiBeckley

AtaiBeckley Inc. (NASDAQ: ATAI) announced it had completed dosing the final patient in its Phase 2b Elumina trial evaluating VLS-01, which is an investigational oral transmucosal film formulation of NN-Dimethyltryptamine (DMT), for adults with treatment-resistant depression (TRD). According to the company; the international, randomized, double-blind, placebo-controlled study enrolled 156 patients, with topline efficacy and safety data expected in the fourth quarter of 2026.

The completion of patient dosing marked a key operational milestone for AtaiBeckley as it advances its late-stage pipeline of rapid-acting mental health therapies. Elumina is designed to evaluate the efficacy, safety and tolerability of repeated dosing of VLS-01, with the primary endpoint measuring changes in depression severity after 29 days.

Beyond the ongoing TRD study, AtaiBeckley also outlined broader development ambitions for the program. Subject to positive Phase 2 results and regulatory alignment, the company intends to advance VLS-01 into a Phase 3 program in major depressive disorder (MDD), while also viewing generalized anxiety disorder (GAD) as a future expansion opportunity.

Chief Executive Officer at AtaiBeckley, Srinivas Rao, said completing enrollment keeps the company on schedule while defining the next stage of development for the asset. “Completing enrollment and dosing the last patient in Elumina keeps us on track for an anticipated topline readout in Q4 2026 and marks the strategic moment to articulate where this program goes next.”

Additionally, Rao said the company’s strategy is to position its two-lead psychedelic-based therapies across different segments of depressive illness. “With BPL-003 advancing in treatment-resistant depression through our recently initiated Phase 3 program, we have the opportunity to direct VLS-01 toward patients across the broader spectrum of depressive illness. We intend to advance VLS-01 into major depressive disorder in Phase 3, subject to supportive Phase 2 results.”

He added that generalized anxiety disorder also represents a significant long-term opportunity, noting that VLS-01’s design fits within a two-hour treatment session, making it well suited for conditions that may require repeat treatments over time.

If successful, VLS-01 would complement AtaiBeckley’s lead asset, BPL-003, which is already in Phase 3 development for treatment-resistant depression and has received FDA Breakthrough Therapy Designation. Together, the company believes the two programs could address patients across a broad spectrum of mood and anxiety disorders.